All In Biotech

Drug Trial Radar · NCT05158387

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.

A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations (TITANIA)

Last checked: Nov 20, 2026Latest source record: Apr 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,172 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,172

Actual

Start

Feb 7, 2022

Primary completion

Jan 19, 2026

Study completion Mar 22, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Dec 15, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab Dose 1 and Dose 2 administered subcutaneously (SC) in adult participants with symptomatic COPD and history of ≥ 2 moderate or ≥ 1 severe exacerbation of COPD in the previous 12 months. Participants should be receiving optimised treatment with maintenance inhaled therapy (ICS/LABA/LAMA triple therapy, or dual therapy if triple is not considered appropriate) in stable doses throughout at least 3 months prior to enrolment.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

  • TozorakimabDrug

    Administered subcutaneously tozorakimab Dose 1 and placebo through Week 52.

  • TozorakimabDrug

    Administered subcutaneously tozorakimab Dose 2 through Week 52.

  • PlaceboDrug

    Placebo administered subcutaneously, equivalent volume to tozorakimab through week 52.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized rate of moderate to severe COPD exacerbations in participants who are former smokers.Time frame: over 52 weeks

Locations

212 sites in 20 countries. Site status is shown where the registry gives one.

  • Research Site

    Sheffield, Alabama

  • Research Site

    Lincoln, California

  • Research Site

    Newport Beach, California

  • Research Site

    Northridge, California

  • Research Site

    Colorado Springs, Colorado

  • Research Site

    Newark, Delaware

  • Research Site

    Bay Pines, Florida

  • Research Site

    Cape Coral, Florida

  • Research Site

    Pensacola, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Winter Park, Florida

  • Research Site

    Macon, Georgia

  • Research Site

    Greenwood, Indiana

  • Research Site

    Bowling Green, Kentucky

  • Research Site

    White Marsh, Maryland

  • Research Site

    North Dartmouth, Massachusetts

  • Research Site

    Ann Arbor, Michigan

  • Research Site

    Farmington Hills, Michigan

  • Research Site

    Grand Rapids, Michigan

  • Research Site

    Buffalo, New York

  • Research Site

    The Bronx, New York

  • Research Site

    Toledo, Ohio

  • Research Site

    Oklahoma City, Oklahoma

  • Research Site

    Tulsa, Oklahoma

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Rock Hill, South Carolina

  • Research Site

    Amarillo, Texas

  • Research Site

    Boerne, Texas

  • Research Site

    Fort Worth, Texas

  • Research Site

    McKinney, Texas

  • Research Site

    Tomball, Texas

  • Research Site

    Webster, Texas

  • Research Site

    Williamsburg, Virginia

  • Research Site

    Cudahy, Wisconsin

  • Research Site

    Campbelltown, Australia

  • Research Site

    Frankstown, Australia

  • Research Site

    Macquarie University, Australia

  • Research Site

    Melbourne, Australia

  • Research Site

    Nedlands, Australia

  • Research Site

    Southport, Australia

Showing 40 of 212 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.